AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

NASDAQ:ATOSAtossa Genetics Stock Price, Forecast & News

$2.73
+0.21 (+8.33 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.58
Now: $2.73
$2.78
50-Day Range
$1.53
MA: $2.03
$2.52
52-Week Range
$0.75
Now: $2.73
$3.25
Volume796,300 shs
Average Volume517,070 shs
Market Capitalization$25.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Read More
Atossa Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATOS
CUSIPN/A
Phone206-325-6086

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.37 per share

Profitability

Net Income$-17,240,000.00

Miscellaneous

Employees4
Market Cap$25.14 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions

How has Atossa Genetics' stock been impacted by COVID-19 (Coronavirus)?

Atossa Genetics' stock was trading at $0.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATOS shares have increased by 210.2% and is now trading at $2.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Atossa Genetics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atossa Genetics.

When is Atossa Genetics' next earnings date?

Atossa Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Atossa Genetics.

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc (NASDAQ:ATOS) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.07. View Atossa Genetics' earnings history.

When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?

Atossa Genetics's stock reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for ATOS?

1 Wall Street analysts have issued twelve-month target prices for Atossa Genetics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Atossa Genetics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price. View analysts' price targets for Atossa Genetics.

Has Atossa Genetics been receiving favorable news coverage?

News coverage about ATOS stock has been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Atossa Genetics earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAtossa Genetics.

Are investors shorting Atossa Genetics?

Atossa Genetics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 256,300 shares, an increase of 7.1% from the April 30th total of 239,400 shares. Based on an average trading volume of 546,300 shares, the days-to-cover ratio is presently 0.5 days. Approximately 2.8% of the company's stock are sold short. View Atossa Genetics' Current Options Chain.

Who are some of Atossa Genetics' key competitors?

What other stocks do shareholders of Atossa Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Biopharmx (BPMX), Amarin (AMRN), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Vaxart (VXRT), Biocept (BIOC) and Gevo (GEVO).

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the following people:
  • Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
  • Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
  • Dr. Jack Cuzick, Member of Scientific Advisory Board

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

How do I buy shares of Atossa Genetics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of ATOS stock can currently be purchased for approximately $2.73.

How big of a company is Atossa Genetics?

Atossa Genetics has a market capitalization of $25.14 million. Atossa Genetics employs 4 workers across the globe.

What is Atossa Genetics' official website?

The official website for Atossa Genetics is www.atossagenetics.com.

How can I contact Atossa Genetics?

Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.